Technical Analysis for PMN - ProMIS Neurosciences Inc.

Grade Last Price % Change Price Change
F 1.15 -9.45% -0.12
PMN closed down 9.45 percent on Friday, November 1, 2024, on 1.35 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
Earnings due: Nov 12
*** please verify all earnings dates ***
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Up

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Inside Day Range Contraction 0.00%
Upper Bollinger Band Touch Strength 0.00%
20 DMA Support Bullish -9.45%
Crossed Above 50 DMA Bullish -9.45%
Expansion Pivot Buy Setup Bullish Swing Setup -9.45%
Pocket Pivot Bullish Swing Setup -9.45%
Reversal New Highs Setup Bullish Swing Setup -9.45%
Volume Surge Other -9.45%

   Recent Intraday Alerts

Alert Time
Down 10% about 17 hours ago
Possible Inside Day about 18 hours ago
50 DMA Support about 21 hours ago
2x Volume Pace about 21 hours ago
Down 5% about 21 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

ProMIS Neurosciences Inc. Description

ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biology Disease Alzheimer's Disease Parkinson's Disease Neurological Disorders Neurodegenerative Diseases Dementia Amyotrophic Lateral Sclerosis Lewy Body Dementia Neurodegenerative Disease Treatment Of Neurodegenerative Diseases Multiple System Atrophy Neuropathology Alpha Synuclein

Is PMN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 3.1
52 Week Low 0.92
Average Volume 79,844
200-Day Moving Average 1.69
50-Day Moving Average 1.18
20-Day Moving Average 1.04
10-Day Moving Average 1.05
Average True Range 0.15
RSI (14) 53.70
ADX 33.07
+DI 27.16
-DI 7.79
Chandelier Exit (Long, 3 ATRs) 1.13
Chandelier Exit (Short, 3 ATRs) 1.36
Upper Bollinger Bands 1.18
Lower Bollinger Band 0.89
Percent B (%b) 0.89
BandWidth 27.93
MACD Line -0.02
MACD Signal Line -0.05
MACD Histogram 0.0324
Fundamentals Value
Market Cap 21.72 Million
Num Shares 18.9 Million
EPS -1.89
Price-to-Earnings (P/E) Ratio -0.61
Price-to-Sales 5168.19
Price-to-Book 5.54
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.48
Resistance 3 (R3) 1.51 1.43 1.43
Resistance 2 (R2) 1.43 1.34 1.41 1.41
Resistance 1 (R1) 1.29 1.29 1.25 1.26 1.39
Pivot Point 1.20 1.20 1.18 1.19 1.20
Support 1 (S1) 1.07 1.12 1.02 1.04 0.91
Support 2 (S2) 0.98 1.07 0.97 0.89
Support 3 (S3) 0.84 0.98 0.87
Support 4 (S4) 0.82